Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

William Suddath

Interventional Cardiology Washington, DC Medical Doctor

NPI 1104876333 CMS profile 4543

110 Irving St Nw, Room # 4B-1, Washington, DC 20010

Open in the dashboard

General payments

$5,102

128 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, William Suddath of Washington, DC is reported in the CMS Open Payments database as having received $5,102 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 39th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $21 1
2023 General $606 21
2022 General $567 27
2021 General $381 13
2020 General $472 23
2019 General $3,056 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Suddath
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to William Suddath were reported at $0. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year William Suddath Interventional Cardiology median Middle half National median
2019 $3,056 $1,097 $329–$3,048 $163
2020 $472 $473 $161–$1,480 $114
2021 $381 $677 $233–$1,827 $132
2022 $567 $978 $333–$2,724 $149
2023 $606 $1,136 $382–$2,986 $160
2024 $21 $1,181 $395–$3,326 $164
2025 $0 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $2,520 14 payments
  2. Medtronic, Inc. $575 13 payments
  3. AstraZeneca Pharmaceuticals LP $265 12 payments
  4. Pfizer Inc. $264 14 payments
  5. Novartis Pharmaceuticals Corporation $249 14 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $216 11 payments
  7. Merck Sharp & Dohme Corporation $215 10 payments
  8. Janssen Pharmaceuticals, Inc $187 10 payments
  9. Amgen Inc. $123 5 payments
  10. Chiesi USA, Inc. $85 5 payments
  11. Other $403 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,852 126 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,250 2 payments
Products named General payments · program years 2019–2024
  1. LifeVest $2,520 14 payments
  2. ONYX FRONTIER $446 11 payments
  3. JARDIANCE $216 11 payments
  4. VERQUVO $215 10 payments
  5. BRILINTA $204 11 payments
  6. XARELTO $187 10 payments
  7. VYNDAQEL $178 9 payments
  8. ENTRESTO $176 10 payments
  9. ELIQUIS $142 8 payments
  10. Repatha $123 5 payments
  11. Other $861 40 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record